Lexaria Bioscience Corp. has been featured in an editorial by Network Newswire ("NNW"), one of the 50plus trusted brands that make up the Investor Brand Network.
FREMONT, CA: Lexaria Bioscience Corp. has been featured in an editorial by Network News Wire ("NNW"), one of the 50+ trusted brands that make up the Investor Brand Network (IBN) multifunctional financial news and publishing organization for private and public companies.
Hypertension, or high blood pressure, is prevalent in the United States. In the United States, an estimated 45 percent of adults, or 108 million individuals, have hypertension, yet roughly one out of every four has it under control. This is a significant issue since hypertension raises the risk of heart disease and stroke, the nation's No. 1 and No. 5 leading causes of death, respectively, each year. According to the CDC, hypertension is a primary or contributing factor in approximately half a million deaths in the United States each year.
Treatments for hypertension vary from meditation to traditional medications, with a potential new invention from Lexaria Bioscience Corp. Lexaria demonstrates that its proprietary DehydraTECH(TM) technology consistently produces robust therapeutic responses while avoiding the adverse side effects of today's medications. Lexaria wants to compete with the market's current majors, who are making immense money addressing high blood pressure and other primary causes of mortality.
DehydraTECH(TM), a Lexaria Biosciences unique drug-delivery technology, optimizes the way active pharmaceutical ingredients (APIs) enter the bloodstream by encouraging healthier oral consumption methods and boosting the efficacy of fat-soluble active molecules, resulting in reduced overall dose. The organization's technology may be used to make foods, beverages, oral suspensions, pills, and capsules, among other ingestible products.